Enterprise
Myeloproliferative Disorders (MPD)
Leukemia Insights - Spring 2007
The development of novel therapies for patients with MPD has been historically hampered by limited understanding of the abnormal processes and molecular causes of these diseases. The discovery of JAK2 mutation in most MPD patients is a first step in this direction. Agents potentially able to interfere with identified abnormalities in MPD are becoming available. Participation in clinical trials of novel agents is warranted. Available programs are listed below.| Therapy | MF | ET | PV | Open to Patients |
|---|---|---|---|---|
Pegylated Interferon α (Pegasys) |
| X | X | X |
| Revlimid (Lenalidomide ) + Prednisone | X |
|
| X |
Bortezomib (Velcade) | X |
|
| X |
Dasatinib (Sprycel) | X |
| X | X |
Obatoclax (pan bcl-2 inhibitor) | X |
|
| X |
Sunitinib (Suniteb) | X |
|
| X |
GC-1008 (antibody against TGF-b) | X |
|
| March-April 2007 |
Pomalidomide (CC-4047) | X |
|
| March-April 2007 |
JAK2 inhibitor | X |
|
| March-April 2007 |
For additional information about the therapies for MPD at M. D. Anderson Cancer Center, visit the myeloproliferative disorders page or contact Srdan Verstovsek, MD, PhD, MPD Program Leader, at (713) 745-3429; e-mail sverstov@mdanderson.org.